Is it time to buy these 2 hot ASX healthcare shares?

The 2 ASX healthcare shares in this article are looking hot. Is it time to buy them? One of those is Volpara Health Technologies Ltd (ASX:VHT).

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are some ASX healthcare shares that are creating a lot of growth at the moment. Is it time to buy them?

Healthcare is one of the largest sectors on the ASX with a number of major companies with global earnings such as CSL Limited (ASX: CSL), Ramsay Health Care Limited (ASX: RHC) and Cochlear Limited (ASX: COH).

But there are some smaller ones that are expanding their market share and growing revenue:

Volpara Health Technologies Ltd (ASX: VHT)

Volpara is a medical technology business that provides clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement and patient tracking.

In the recent update for the third quarter of FY21 it said that it generated its largest-ever third quarter sales performance, with annual recurring revenue (ARR) reaching NZ$20.7 million at the time. Its average revenue per user (ARPU) at US$1.22 – up 5% from the second quarter.

Also, last month, the ASX healthcare share announced the acquisition of CRA Health. It's described as an industry leader in breast cancer risk assessment spun out from Massachusetts General Hospital, a Harvard Medical School teaching hospital.

For Volpara, CRA adds ARR of over US$4 million, average revenue per user (ARPU) of around US$1.70 and coverage of around 6% of US breast screenings.

CRA's software is integrated with the major electronic health record (EHR) and genetics companies.

Volpara will have ARR of around US$17.5 million and at least one product used in over 30% of US breast screenings.

Broker Morgans has a share price target for Volpara of $1.92, suggesting potential upside of close to 40%. The broker is a fan of the CRA acquisition and likes the increasing market share of women breast screenings.

Pro Medicus Ltd (ASX: PME)

Despite recent share sales by the founders of the business, the share price keeps heading higher.

Pro Medicus describes itself as a leading medical imaging IT provider. It offers a full range of radiology IT software and services to hospitals, imaging centres and health care groups worldwide. Visage Imaging is the key software offering.

The ASX healthcare share has been successfully winning many of the large contracts that have been on offer in both Europe and North America. This will drive earnings higher in the coming years, as they are multi-year contracts.

In the recent FY21 half-year result it reported that revenue rose 7.8% to $31.6 million, underlying profit before tax grew 25.9% to $18.8 million and net profit after tax (NPAT) grew 12.4% to $13.5 million. The earnings before interest and tax (EBIT) margin was around 59%, its cash reserve grew $7.5 million to $50.9 million and the interim dividend was increased by 16.6% to $0.07 per share.

Morgans is not convinced that the current Pro Medicus share price represents good value. It has a share price target of $41.30 for the ASX healthcare share. However, it said the result was strong as the business recovers from COVID-19 impacts.

The broker believes that Pro Medicus can generate earnings per share (EPS) of 42 cents for FY22, meaning it's valued at 110x FY22's estimated earnings.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. and VOLPARA FPO NZ. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd., Pro Medicus Ltd., Ramsay Health Care Limited, and VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »